Every DEF 14A that Akari Therapeutics plc (AKTX) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow AKTX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full AKTX filings page.
Akari Therapeutics Plc asks shareholders to approve a 144,000,000,000-ordinary-share increase in the 2023 Equity Incentive Plan reserve, from 19,806,000,000 to 163,806,000,000 ordinary shares. The proposal also permits up to 855,637,300 ordinary shares tied to 2014 Plan awards that are forfeited or cancelled, or expire unexercised. The Board approved the increase subject to shareholder approval at the October 28, 2026 meeting and says the expanded pool would support long-term equity incentives for employees, consultants and directors.
As of October 1, 2026, 16,272,945,001 ordinary shares were subject to outstanding options under the 2023 and 2014 Plans, at a weighted average exercise price of $0.00055; 1,200,000,000 shares were subject to unvested, performance-based restricted stock units, and 484,739,210 shares remained available under the 2023 Plan. Akari reported 182,813,169,533 issued and outstanding ordinary shares as of September 30, 2026. Ordinary-share proxy forms are due to Equiniti by 2:30 p.m. London time on October 26, 2026; ADS proxy cards are due to Deutsche Bank by 1:00 p.m. Eastern Time on October 19, 2026. The Board unanimously recommends voting FOR.
Akari Therapeutics, Plc is asking shareholders to vote at its June 30, 2026 annual general meeting on 18 resolutions covering financial reports, pay, board elections, auditors and major share issuance authorities.
Shareholders will vote on receiving the 2025 statutory accounts, the U.K. directors’ remuneration report and a revised three‑year remuneration policy, plus a non‑binding “say‑on‑pay” for named executive officers. The company proposes re‑electing six Class A directors and ratifying BDO USA, P.C. as independent registered public accounting firm, alongside re‑appointing HaysMac LLP as U.K. statutory auditor.
Several capital resolutions seek approval under Nasdaq rules for a $25,000,000 equity line with White Lion Capital, warrants to purchase up to 4,411,764 ADSs plus 117,647 placement‑agent ADSs, and a potential private placement that could be deemed a change of control. The board also asks authority to allot up to USD 20,000 nominal share capital, equivalent to 4,000,000,000,000 ordinary shares (50,000,000 ADSs), and to disapply pre‑emption rights through June 30, 2031. The board unanimously recommends voting in favor of all resolutions.
Akari Therapeutics, Plc is asking shareholders to approve the exercisability of several warrant issuances tied to recent financings and a note exchange. Five ordinary resolutions cover Series G Warrants, Pre-Funded Warrants, Note Exchange Warrants and Placement Agent Warrants issued in a registered direct offering, a concurrent private placement and a note exchange completed in December 2025 and January 2026.
The proposals would permit exercise of warrants for up to 10,043,774 ADSs plus 504,300 ADSs from placement agent warrants in the registered direct deal, 5,127,426 ADSs from the private placement, and 19,005,406 ADSs from the note exchange. If all Pre-Funded, Series G, Note Exchange and Placement Agent Warrants are exercised for cash, Akari states it could receive approximately $8.9 million in gross proceeds.
The board unanimously recommends voting in favor of each warrant exercise proposal and explains that without approval, the warrants cannot be exercised and the company would need to call additional shareholder meetings, adding cost. The proxy also explains detailed voting procedures for ordinary shareholders and ADS holders and outlines current major shareholdings.
Akari Therapeutics is asking shareholders to approve several key proposals at a general meeting on December 15, 2025. The main item is approval of the exercisability of warrants for up to 6,375,000 ADSs issued in an October 2025 financing, with exercise prices of $0.98 for the investor warrants and $1.00 for the placement agent warrants, which could raise about $6.25 million if fully exercised in cash.
Shareholders are also being asked to restructure the share capital by subdividing each $0.0001 ordinary share into one $0.000000005 ordinary share and 19,999 deferred shares, then buying back and cancelling the deferred shares. Additional proposals would authorize directors to allot shares up to a $3,000 nominal amount, disapply pre-emption rights for cash issuances until June 30, 2030, and adopt new articles of association. The board unanimously recommends voting in favor of all resolutions.